{
  "citations" : [],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166265162",
    "name" : "Annotation of DPWG Guideline for carbamazepine and HLA-B",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : false,
    "hasTestingInfo" : true,
    "history" : [
      {
        "id" : 1451704264,
        "date" : "2022-03-03T16:33:36.803-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451706223,
        "date" : "2022-03-07T15:46:12.789-08:00",
        "description" : "Corrected typo",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451732903,
        "date" : "2022-03-28T09:57:50.464-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451884122,
        "date" : "2022-09-16T09:52:05.588-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146473,
        "date" : "2023-07-03T13:39:54.912-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452411931,
        "date" : "2024-03-18T12:46:02.993-07:00",
        "description" : "Updated links for risk analysis pdf.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452411933,
        "date" : "2024-03-18T12:50:49.501-07:00",
        "description" : "Added testing section and tag",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452413046,
        "date" : "2024-03-19T08:27:44.384-07:00",
        "description" : "Added alternative drug tag.",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [],
    "otherPrescribingGuidance" : false,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [
      {
        "objCls" : "Haplotype",
        "id" : "PA165954769",
        "symbol" : "HLA-B*15:02",
        "name" : "*15:02",
        "version" : 5
      },
      {
        "objCls" : "Haplotype",
        "id" : "PA165954787",
        "symbol" : "HLA-B*15:11",
        "name" : "*15:11",
        "version" : 6
      }
    ],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA448785",
        "name" : "carbamazepine",
        "version" : 14
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA35056",
        "symbol" : "HLA-B",
        "name" : "major histocompatibility complex, class I, B",
        "version" : 40
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1451697780,
      "html" : "<p>Consider an alternative drug to carbamazepine in patients with the HLA-B*15:02 or HLA-B*15:11 alleles.</p>\n",
      "version" : 1
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1451697743,
      "html" : "<p>Read more about how PharmGKB <a href=\"/page/dpwgMapping\">curates DPWG guidelines</a> using extra information provided by DPWG to enable the interactive genotype tool above.</p>\n<h3 id=\"may-2021-guideline\">May 2021 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated recommendations for carbamazepine based on the presence of the HLA-B*15:02 or *15:11 alleles.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_May_2021.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_May_2021.pdf\">Dutch guidelines May 2021 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>HLA-B*1502</td>\n<td>carbamazepine</td>\n<td>Patients with this genetic variation (HLA-B*1502) have a severely increased risk of experiencing the life-threatening cutaneous adverse event Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). The risk of carbamazepine-induced SJS/TEN in these patients is 1.8-3.4%.</td>\n<td>1. choose an alternative if possible Phenytoin, lamotrigine and oxcarbazepine also pose an increased risk of SJS/TEN in these patients, but the final risk is 10-fold lower for these medicines than for carbamazepine. Furthermore, in the case of oxcarbazepine, the most severe forms (SJS/TEN overlap and TEN) have not been observed.</td>\n</tr>\n<tr>\n<td>HLA-B*1511</td>\n<td>carbamazepine</td>\n<td>Patients with this genetic variation (HLA-B*1511) have an increased risk of experiencing the life-threatening cutaneous adverse event Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). The risk of carbamazepine-induced SJS/TEN in patients with the HLA-B*1502 allele, which carries a 4.6-6.6 times higher risk than the HLA-B*1511 allele, is 1.8- 3.4%. This would equate to a risk of carbamazepine-induced SJS/TEN in these patients of 0.27-0.73%.</td>\n<td>1. carefully weigh the risk of SJS/TEN against the benefits 2. if an alternative is an option, choose an alternative</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_HLA_carbamazepine_6237-6238-6239.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_HLA_carbamazepine_6237-6238-6239.pdf\">Read for more information about this recommendation</a>, <a download=\"HLAs.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/HLAs.pdf\">Read about gene information from DPWG</a></p>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a download=\"DPWG_HLA_carbamazepine_6237-6238-6239.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_HLA_carbamazepine_6237-6238-6239.pdf\">DPWG risk analysis document</a> for carbamazepine and HLAs:</p>\n<blockquote class=\"blockquote\">\n<p>The KNMP Pharmacogenetics Working Group considers HLA-B*1502 genotyping of patients of Asian, other than\nJapanese descent, HLA-A*3101 genotyping, and HLA-B*1511 genotyping of patients of Han Chinese, Korean, Thai\nor Japanese descent before starting carbamazepine to be beneficial for drug safety. It is advised to consider genotyping these patients before (or directly after) drug therapy has been initiated to guide drug selection.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n",
      "version" : 6
    },
    "version" : 8
  }
}